Chemoimmunotherapy in patients with extensive-stage small cell lung cancer and a poor performance status.

Abstract

Immune checkpoint inhibitor combined with platinum-etoposide is the standard first-line therapy for patients with extensive-stage small cell lung cancer (ES-SCLC). The phase 3 clinical trials that led to the approval of chemoimmunotherapy in ES-SCLC excluded patients who had an Eastern Cooperative Group (ECOG) performance status (PS) of 2-3. Therefore, data on the efficacy of chemoimmunotherapy in patients with an ECOG PS of 2-3 are limited. A retrospective analysis was performed on patients diagnosed with ES-SCLC who received chemoimmunotherapy (atezolizumab or durvalumab) within the Mayo Clinic Health System between January 2016 and January 2021. The objective of this study was to compare the overall survival (OS), progression-free survival (PFS), and best clinical response to therapy in patients with an ECOG PS of 0-1 vs. patients with an ECOG PS of 2-3 who received chemoimmunotherapy for newly diagnosed ES-SCLC. In total, 82 patients were included in the study. The mean±standard deviation age was 68.1±8.3 years. Of these, 56 patients were identified with an ECOG PS of 0-1, and 26 patients were identified with an ECOG PS of 2-3. The median PFS was similar regardless of ECOG PS (5.8months [95% CI, 4.3-6.0 months] in the ECOG PS 0-1 group vs. 4.1months [95% CI, 3.8-6.9 months] in the ECOG PS 2-3; p=.2994). The median OS was also similar regardless of ECOG PS (10.6months [95% CI, 8.4-13.4 months] in the ECOG PS 0-1 group vs. 9.3months [95% CI, 4.9-12.8 months]; p=.2718) in the ECOG PS 2-3 group. The study results demonstrated no significant difference in PFS or OS among the ECOG PS 2-3 and ECOG PS 0-1 groups. Therefore, chemoimmunotherapy should be considered for patients who have ES-SCLC with an ECOG PS of 2-3.